Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Jan. 21, 2026	Dec. 31, 2025	Feb. 28, 2025	Jan. 28, 2021	Mar. 09, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Estimated fair value of deferred royalty obligation under funding agreement, net embedded derivative liability	$ 554.7			$ 565.5
Gain for change in fair value of embedded derivative liability	$ 2.2	$ 4.0
2033 Notes, net \| Convertible Debt
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Stated interest rate	0.75%		0.75%
2031 Notes, net \| Convertible Debt
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Stated interest rate	1.75%				1.75%
2029 Notes, net \| Convertible Debt
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Stated interest rate	2.25%					2.25%
2027 Notes, net \| Convertible Debt
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Stated interest rate	2.50%						2.50%
Amended Loan Agreement
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of amount outstanding	$ 343.7			$ 343.0

BridgeBio Pharma, Inc. 10-Q